Anne O'Riordan reports 3,507 RSUs grant and 1,805-share sale at $111.25

Rhea-AI Filing Summary

Anne O'Riordan, a director of Jazz Pharmaceuticals plc (JAZZ), filed a Form 4 reporting a grant of restricted stock units and a sale to cover taxes. On 08/07/2025 she was granted 3,507 restricted stock units under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan; each unit represents a contingent right to one ordinary share and these units vest in full on July 24, 2026 subject to continuous service and additional conditions. On 08/08/2025 she sold 1,805 shares at $111.2494 per share to satisfy tax obligations arising from the vesting of previously granted RSUs. The filing shows beneficial ownership of 18,305 shares following the grant and 16,500 shares following the sale. The Form 4 was signed by an attorney-in-fact on 08/11/2025.

Insights

Corporate Governance Expert

TL;DR: Director O'Riordan received RSUs and executed a sale-to-cover; both are standard director compensation and tax-management activities.

The filing documents a non-employee director award of 3,507 restricted stock units under the company's 2007 directors plan, with vesting conditioned on continued service and settling on July 24, 2026. The subsequent sale of 1,805 shares at $111.2494 is explicitly described as to satisfy tax obligations from prior RSU vesting. From a governance perspective, these entries are routine disclosures of equity-based compensation and related tax withholding; the form records direct beneficial ownership levels before and after the transactions.

Securities Analyst

TL;DR: Transaction details are transparent: RSU grant (3,507 units) and an 1,805-share sale at $111.2494 to cover taxes; no extraordinary items reported.

The Form 4 lists an A code RSU grant on 08/07/2025 and an F code sale on 08/08/2025 of 1,805 shares at $111.2494 per share. Beneficial ownership is reported as 18,305 shares after the grant and 16,500 shares after the sale. The disclosure follows standard Section 16 reporting conventions and provides clear numeric detail for monitoring insider holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORiordan Anne

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/07/2025		A(1)		3,507	A	$0.0	18,305	D
Ordinary Shares	08/08/2025		F(2)		1,805	D	$111.2494	16,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.

2. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

	By: /s/Adam Guttmann, as attorney in fact For: Anne O'Riordan	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Anne O'Riordan report on her JAZZ Form 4?

She reported a grant of 3,507 restricted stock units on 08/07/2025 and the sale of 1,805 JAZZ shares on 08/08/2025.

When do the restricted stock units granted to Anne O'Riordan vest?

The 3,507 restricted stock units vest in full on July 24, 2026, subject to continuous service and additional conditions.

How many shares did Anne O'Riordan sell and at what price?

She sold 1,805 shares at a price of $111.2494 per share to satisfy tax obligations.

What was Anne O'Riordan's beneficial ownership after the reported transactions?

Beneficial ownership is reported as 18,305 shares following the RSU grant and 16,500 shares following the sale.

Who signed the Form 4 on behalf of Anne O'Riordan?

The Form 4 was signed by Adam Guttmann, as attorney-in-fact for Anne O'Riordan, dated 08/11/2025.